Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nunn

Showing results (271-280 of 285) with videos related to

Pageof 29
Sort By:
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe|April 12, 2008
Inequalities in access to education and healthcareJ Nunn, R Freeman, E Anderson, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The New England Journal of Medicine|February 22, 2023
Treatment Strategy for Rifampin-Susceptible TuberculosisNicholas I Paton, Christopher Cousins, Celina Suresh, et al.
The Lancet. Global Health|December 24, 2022
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trialLaura Rosu, Jason J Madan, Ewan M Tomeny, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
Environmental Pollution (Barking, Essex : 1987)|June 24, 2010
Enhanced ozone strongly reduces carbon sink strength of adult beech (Fagus sylvatica)--resume from the free-air fumigation study at Kranzberg ForestR Matyssek, G Wieser, R Ceulemans, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
Pageof 29

Showing results (271-280 of 285) with videos related to

Sort By:
Pageof 29
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe|April 12, 2008
Inequalities in access to education and healthcareJ Nunn, R Freeman, E Anderson, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The New England Journal of Medicine|February 22, 2023
Treatment Strategy for Rifampin-Susceptible TuberculosisNicholas I Paton, Christopher Cousins, Celina Suresh, et al.
The Lancet. Global Health|December 24, 2022
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trialLaura Rosu, Jason J Madan, Ewan M Tomeny, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
Environmental Pollution (Barking, Essex : 1987)|June 24, 2010
Enhanced ozone strongly reduces carbon sink strength of adult beech (Fagus sylvatica)--resume from the free-air fumigation study at Kranzberg ForestR Matyssek, G Wieser, R Ceulemans, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
Pageof 29